In contrast to pan-PI3K inhibitors, development of which was limited by toxicity [19,20,21], alpelisib can be administered safely in patients with HR+, HER2–, PIK3CA-mutated breast cancer, although adverse events (AEs) associated with PI3K inhibition are common [17,22]. Here, ERBB2 is linked to breast carcinoma.